Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.
2.
3.
4.
5.
7.

The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment.

Foged NT, Brügmann A, Jørgensen JT.

Expert Rev Mol Diagn. 2013 Apr;13(3):233-42. doi: 10.1586/erm.13.6.

PMID:
23570400
8.

Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.

Vocaturo A, Novelli F, Benevolo M, Piperno G, Marandino F, Cianciulli AM, Merola R, Donnorso RP, Sperduti I, Buglioni S, Mottolese M.

Oncologist. 2006 Sep;11(8):878-86.

10.

Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.

Hwang CC, Pintye M, Chang LC, Chen HY, Yeh KY, Chein HP, Lee N, Chen JR.

Histopathology. 2011 Nov;59(5):984-92. doi: 10.1111/j.1365-2559.2011.04037.x.

PMID:
22092410
11.

Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.

Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM.

Clin Cancer Res. 2004 Jul 15;10(14):4793-8.

12.
13.

[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].

Akhdar A, Bronsard M, Lemieux R, Geha S.

Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Review. French.

PMID:
22172120
14.

Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).

Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY.

Pathol Int. 2010 Jul;60(7):510-5. doi: 10.1111/j.1440-1827.2010.02553.x.

PMID:
20594272
15.

Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.

Viale G, Paterson J, Bloch M, Csathy G, Allen D, Dell'Orto P, Kjærsgaard G, Levy YY, Jørgensen JT.

Pathol Res Pract. 2016 Aug;212(8):735-42. doi: 10.1016/j.prp.2016.06.002. Epub 2016 Jun 8.

16.

Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.

Wixom CR, Albers EA, Weidner N.

Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):248-51.

PMID:
15551739
17.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F.

BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351.

18.

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.

Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, Zhang W, Grogan TM, Lee CT, Jheon S, Chung JH.

J Thorac Oncol. 2011 Aug;6(8):1359-66. doi: 10.1097/JTO.0b013e31821cfc73.

19.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

20.

Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.

García-Caballero T, Prieto O, Vázquez-Boquete A, Gude F, Viaño P, Otero M, Curiel T, Fernández-Rodríguez B, Parrado C, Fraga M, Antúnez JR.

Breast Cancer Res Treat. 2014 Jan;143(1):81-9. doi: 10.1007/s10549-013-2791-8. Epub 2013 Nov 30.

PMID:
24292870

Supplemental Content

Support Center